Patents by Inventor Ingemar Starke

Ingemar Starke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1,5-Benzothiazepines and their use as hypolipidaemics
    Patent number: 6906058
    Abstract: The present invention relates to compounds of formula (I) wherein R1 and R2 are independently selected from C1-6alkyl; one of R4 and R5 is a group of formula (IA): R3, R6, R7, R8, R9, R10 and R11 and the other of R4 and R5 are as defined within, pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and there use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Grant
    Filed: March 5, 2001
    Date of Patent: June 14, 2005
    Assignee: AstraZeneca AB
    Inventors: Ingemar Starke, Mickael Dahlström, David Blomberg
  • Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
    Publication number: 20050101611
    Abstract: An oral pharmaceutical formulation comprising an inhibitor compound of the ileal bile acid transport (IBAT inhibitor), an HMG Co-A reductase inhibitor and a therapeutically acceptable carrier characterised in that the formulation is designed to deliver the IBAT inhibitor in the ileum and the HMG Co A reductase inhibitor non-specifically into the GI tract. The IBAT inhibitor compound and the HMG Co-A reductase inhibitor can also be administered in combination with a bile acid binder to alleviate possible side effects of therapy with IBAT inhibitor compounds, such as for instance diarrhoea. The bile acid binder may be formulated for colon release.
    Type: Application
    Filed: October 12, 2001
    Publication date: May 12, 2005
    Inventors: Ingemar Starke, Bertil Abrahamsson, Anna-Lena Ungell, Ann-Margret Lindqvist
  • Benzothiepine ileal bile acid transport inhibitors
    Publication number: 20050043393
    Abstract: The present invention relates to compounds of formula (I) wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Application
    Filed: September 5, 2002
    Publication date: February 24, 2005
    Inventors: Ingemar Starke, Mikael Dahlstrom, David Blomberg
  • Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
    Publication number: 20050038009
    Abstract: The present invention relates to compounds of formula (I) wherein Rv, R1, R2, Rx, Ry, M, Rz, v, R3, R4, R5 and R6 are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Application
    Filed: September 5, 2002
    Publication date: February 17, 2005
    Inventors: Ingemar Starke, Mikael Dahlstrom, David Blomberg, Suzanne Alenfalk, Tore Skjaret, Malin Lemurell
  • Benzothiazepine derivatives for the treatment of hyperlipidemia
    Publication number: 20050032776
    Abstract: The present invention relates to compounds of formula (I): wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Application
    Filed: September 5, 2002
    Publication date: February 10, 2005
    Inventors: Ingemar Starke, Mikael Ulf Dahlstrom, David Blomberg
  • Benzothiazepine derivatives
    Publication number: 20040254160
    Abstract: The present invention relates to compounds of formula (I), wherein variable groups are as defined within; pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Application
    Filed: July 23, 2004
    Publication date: December 16, 2004
    Inventors: Ingemar Starke, Mikael ulf Johan Dahlstrom, David Blomberg, Suzanne Alenfalk, Peter Nordberg, Andreas Christer Wallberg, Stig Jonas Bostrom
  • Novel imidazopyridine compounds with therapeutic effect
    Publication number: 20040220209
    Abstract: The present invention relates to imidazo pyridine derivatives of the formula (I) whichinhibit exogenously or endogenously stimulated gastric acid secretion and thus can be usedin the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Application
    Filed: February 19, 2004
    Publication date: November 4, 2004
    Inventors: Kosrat Amin, Mikael Dahlstrom, Peter Nordberg, Ingemar Starke
  • Compounds
    Patent number: 6790960
    Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: May 5, 2003
    Date of Patent: September 14, 2004
    Assignee: AstraZeneca AB
    Inventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
  • Chemical compounds
    Publication number: 20040067933
    Abstract: The present invention relates to compounds of the formula (I): (wherein variable groups are as defined within) pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and their use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Application
    Filed: June 20, 2003
    Publication date: April 8, 2004
    Inventors: Ingemar Starke, Mikael Dahlstrom, David Blomberg
  • New compounds
    Publication number: 20030220364
    Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Application
    Filed: May 5, 2003
    Publication date: November 27, 2003
    Inventors: Kosrat Amin, Mikael Dahlstrom, Peter Nordberg, Ingemar Starke
  • 1,5-Benzothiazepines and their use as hypolipidaemics
    Publication number: 20030166927
    Abstract: The present invention relates to compounds of formula (I) wherein R1 and R2 are independently selected from C1-6alkyl; one of R4 and R5 is a group of formula (IA): R3, R6, R7, R8, R9, R10 and R11 and the other of R4 and R5 are as defined within, pharmaceutically acceptable salts, solvates, solvates of such salts and prodrugs thereof and there use as ileal bile acid transport (IBAT) inhibitors for the treatment of hyperlipidaemia. Processes for their manufacture and pharmaceutical compositions containing them are also described.
    Type: Application
    Filed: September 6, 2002
    Publication date: September 4, 2003
    Inventors: Ingemar Starke, Mickael Dahlstrom, David Blomberg
  • Imidazo[1,2-a]pyridine compounds
    Patent number: 6613775
    Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: October 22, 1999
    Date of Patent: September 2, 2003
    Assignee: AstraZeneca AB
    Inventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
  • Compounds
    Patent number: 6579884
    Abstract: The present invention relates to novel compounds, and therapeutically acceptable salts thereof of the formula (I), which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: October 13, 1999
    Date of Patent: June 17, 2003
    Assignee: AstraZeneca AB
    Inventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
  • Heterocyclic compounds for inhibition of gastric acid secretion, processes for their preparation and pharmaceutical compositions thereof
    Patent number: 6518270
    Abstract: The present invention relates to heterocyclic compounds of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: February 8, 2000
    Date of Patent: February 11, 2003
    Assignee: AstraZeneca AB
    Inventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
  • Benzyl-substituted benzimidazoles
    Patent number: 6465505
    Abstract: The present invention relates to benzimidazole derivatives of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: July 17, 1997
    Date of Patent: October 15, 2002
    Assignee: AstraZeneca AB
    Inventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
  • Imidazo pyridine derivatives which inhibit gastric acid secretion
    Patent number: 6313137
    Abstract: The present invention relates to imidazo pyridine derivatives of the formula (I), in which the phenyl moiety is substituted, and in which the imidazo pyridine moiety is substituted with a carboxamide group in 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: November 6, 2001
    Assignee: AstraZeneca AB
    Inventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
  • Imidazo pyridine derivatives which inhibit gastric acid secretion
    Patent number: 6313136
    Abstract: The present invention relates to imidazo pyridine derivatives of the formula (I), in which the phenyl moiety is substituted, and in which the imidazo pyridine moiety is substituted with a carboxamide group in 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: June 14, 1999
    Date of Patent: November 6, 2001
    Assignee: AstraZeneca AB
    Inventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
  • Compounds for inhibition of gastric acid secretion
    Patent number: 6265415
    Abstract: The present invention relates to imidazo pyridine derivatives of the formula (I), in which the phenyl moiety is substituted with lower alkyl in 2- and 6-position, which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: March 10, 1998
    Date of Patent: July 24, 2001
    Assignee: AstraZeneca AB
    Inventors: Kosrat Amin, Mikael Dahlström, Peter Nordberg, Ingemar Starke
  • Active Compounds
    Patent number: 5889021
    Abstract: The present invention relates to novel quinoline derivatives of the formula ##STR1## which inhibit exogenously or endogenously stimulated gastric acid secretion and thus can be used in the prevention and treatment of gastrointestinal inflammatory diseases.
    Type: Grant
    Filed: July 1, 1994
    Date of Patent: March 30, 1999
    Assignee: Astra Aktiebolag
    Inventor: Carl Ingemar Starke
  • Active compounds
    Patent number: 5439917
    Abstract: Therapeutically active compounds of the formula: ##STR1## wherein the variables are defined in the specification are provided.
    Type: Grant
    Filed: September 27, 1993
    Date of Patent: August 8, 1995
    Assignee: Aktiebolaget Astra
    Inventors: Carin Briving, Stig Carlsson, Robert Carter, Marie Elebring, Thomas Kuhler, Peter Nordberg, Ingemar Starke, Arne Svensson